Active substancePirantelePirantele
Similar drugsTo uncover
  • Helmintox
    pills inwards 
  • Helmintox
    suspension inwards 
  • Nemocide
    suspension inwards 
  • Nemocide
    pills inwards 
  • Pirantele
    pills inwards 
    OZONE, LLC     Russia
  • Pirantele
    suspension inwards 
  • Pirantele
    pills inwards 
  • Pirantele
    suspension inwards 
  • Pirantele
    pills inwards 
  • Pirantele
    suspension inwards 
    ATOLL, LLC     Russia
  • Pirantele
    pills inwards 
  • Pirantele
    suspension inwards 
  • Dosage form: & nbspPills.
    Composition:

    Each tablet contains the active substance: pyrantel pamoate 721.0 mg in terms of pyrantel base 250.0 mg.

    Excipients: microcrystalline cellulose - 25.0 mg, sodium carboxymethyl starch - 16.0 mg, potato starch - 30.0 mg, magnesium stearate - 8.0 mg.

    Description:

    The tablets are yellow with a gray-green hue of a flat-cylindrical shape, with a facet on both sides and a risk on one side.

    Pharmacotherapeutic group:Anthelminthic remedy
    ATX: & nbsp

    P.02.C.C.01   Pirantele

    Pharmacodynamics:

    Pyrantel is an antihelminthic agent that acts on nematodes.

    It causes neuromuscular blockade in sensitive helminths, which facilitates their removal from the digestive tract without stimulation and stimulation of migration of affected worms.

    The drug acts on parasites in the early phase of development and on their mature forms, does not affect the larvae during their migration into tissues.

    Pirantel is effective against infestations caused by pinworms (Enterobius vermicularis), hookworms (Ancylostoma doudenale, Necator americanus), against the causative agents of trichocephalosis (Trichostrongylus orientalis and Trichostrongylus colubriformis) and ascariasis (Ascaris lumbricoides).

    Pharmacokinetics:

    Pirantel is very poorly absorbed from the gastrointestinal tract (GIT).

    Concentration of the drug in blood plasma, after oral administration of a single dose of 10 mg / kg body weight, is 0.005-0.13 μg / ml and is achieved within 1 to 3 hours.

    There are no data on the penetration of the drug through the placenta and into the milk of the lactating woman, and also regarding the distribution of the drug in the tissues and body fluids (theoretically, the resorption of the drug is minimal).

    The minimal amount of the drug absorbed in the digestive tract is partially metabolized in the liver before Nmethyl-1,3-propanediamine.

    About 93% of the oral dose of the drug is excreted unchanged in the intestine, and not more than 7% by the kidneys in unchanged form or as a metabolite of N-methyl-1,3-propanediamine.

    Indications:

    • Ascaridosis
    • Enterobiosis
    • Ankylostomiasis
    • Nekatoroz
    • Trichocephalosis

    Contraindications:

    • Hypersensitivity to the drug;
    • myasthenia gravis (treatment period);
    • Children under 3 years old (for this dosage form).

    Carefully:

    Pregnancy, hepatic insufficiency.

    Pregnancy and lactation:

    Application in pregnancy

    There are no controlled studies of the use of pyrantel in pregnant women, so the drug should be used only if the potential benefit to the mother exceeds the possible risk to the fetus.

    Application during lactation

    There are no data on the safety of the drug in lactating women, so the question of stopping breastfeeding for the duration of treatment with the drug should be resolved.

    Dosing and Administration:

    The drug is used during or after a meal, thoroughly chewing the tablet, drinking 1 glass of water.

    If no other treatment regimen is prescribed, depending on the age and body weight of the patient,the following dosages are recommended:

    Patient's age

    Tablets 250 mg

    mg

    3-6 years old

    1

    250

    6-12 years old

    2

    500

    older than 12 years and adults weighing up to 75 kg

    3

    750

    adults with a body weight of more than 75 kg

    4

    1000

    To avoid self-invasion, it is possible to repeat the course 3 weeks after the first dose.

    With isolated ascariasis, the use of pyrantel is recommended at 5 mg / kg, once.

    With ascariasis and enterobiasis, as well as mixed infestations with these parasites, the dose intended for the entire course (at the rate of 10 mg / kg) is applied once.

    With ankylostomiasis, a combination of non-katorosis with ascariasis or other combined helminthic lesions pirantele apply for 3 days to 10 mg / kg per day.

    In massive invasions of Necator americanus, a dose of 20 mg / kg of body weight is recommended for 2 days.

    Side effects:

    Side effects are rare, they are short-lived and disappear after discontinuation of treatment.

    Most side effects are manifested by the gastrointestinal tract: nausea, vomiting, lack of appetite, diarrhea, pain and stomach cramps.

    Headache, dizziness, drowsiness or insomnia, weakness, rash, fever, transient increase in activity of aspartate aminotransferase (ACT) in the serum.

    In isolated cases, there were hearing disorders, hallucinations with confusion and paresthesia (the relationship of these symptoms with taking the drug is not proven).

    Overdose:

    Cases of overdose are not described.

    In case of an overdose, symptomatic treatment should be undertaken.

    Interaction:

    Pyrantel should not be used together with piperazine. These funds act antagonistically.

    Pirantel increases the concentration of theophylline in plasma.

    Special instructions:

    After taking Pirantel laxatives are not prescribed. In the treatment of enterobiasis, all co-residents must be treated simultaneously. Careful hygiene (cleaning of living quarters and cleaning clothes for the destruction of helminth eggs) is a preventive measure of reinfection. 14 days after drug treatment Pirantele should conduct control parasitologic studies.

    Effect on the ability to drive transp. cf. and fur:

    Given the possible side effects of the nervous system during the use of the drug should be careful when dealing with potentially dangerous activities that require increased concentration and speed of psychomotor reactions.

    Form release / dosage:

    Tablets 250 mg.

    Packaging:

    3 tablets per contour cell packaging made of polyvinylchloride film and aluminum foil printed lacquered. By 3, 6, 10, 20, 30, 40, 50 or 100 tablets into a polymer container for medicines. One container or 1, 2, 3, 4, 5 or 10 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

    Storage conditions:

    Store in a dry, dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:

    3 years. Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:PL-000231
    Date of registration:16.02.2011
    The owner of the registration certificate:OZONE, LLC OZONE, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp10.08.2015
    Illustrated instructions
      Instructions
      Up